Get Instant Summarized Text (Gist) Extracellular vesicles (EVs) contain ion channels that maintain their structural integrity and function during cell-to-cell cargo transport. These channels ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently used on a very large scale by the humans of Earth.

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said. A ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.

20. J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...